Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Horizon Discovery, a Cambridge Enterprise company, has signed a three year Technology Access Agreement with the National Institutes of Health (NIH) divisions, the National Cancer Institute (NCI) and the National Human Genome Research Institute (NHGRI).
Subscribe to our email newsletter
Under the collaboration deal, NCI and NHGRI will apply Horizon’s rAAV gene editing technology (GENESIS) to engineer human isogenic disease models for its researchers.
In addition, X-MAN (gene X- Mutant and Normal) cell lines will be developed annually to bolster basic research and translational medicine.
The initial set of 18 projects from eight laboratories will develop disease models for melanoma, prostate, colon and kidney cancer, genes involved with chromatin and chromosome function, and cell lines complementary to existing mouse cancer disease models.